Herpes zoster epidemiology during and after the COVID-19 pandemic: A 5-year retrospective study from primary care in Poland.

IF 2.5 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
Michał Oleszko, Lech Zaręba, Aleksandra Łoś, Nikola Król, Hanna Czajka
{"title":"Herpes zoster epidemiology during and after the COVID-19 pandemic: A 5-year retrospective study from primary care in Poland.","authors":"Michał Oleszko, Lech Zaręba, Aleksandra Łoś, Nikola Król, Hanna Czajka","doi":"10.17219/acem/222571","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Herpes zoster (HZ) is caused by reactivation of latent varicella-zoster virus and affects 25-30% of individuals, with the highest incidence in adults aged ≥50 years and a lifetime risk exceeding 50% after the age of 85. Its most common complication is postherpetic neuralgia (PHN), i.e., persistent neuropathic pain. Reports of increased HZ incidence during or after SARS-CoV-2 infection suggest potential epidemiological associations requiring further investigation.</p><p><strong>Objectives: </strong>Our goals were to evaluate the incidence of HZ and its complications during the pandemic and the post-pandemic period in primary care settings in Poland.</p><p><strong>Material and methods: </strong>We conducted a retrospective multicenter study in 20 primary care clinics in Poland, covering 43,949-81,091 patients from 2020 to 2024. Incident HZ cases and complications (PHN, herpes zoster ophthalmicus (HZO), HZ oticus, and disseminated HZ) were identified, and demographic data, including place of residence, were collected. Statistical analyses included χ2 or Fisher's exact tests, Student's t-tests or nonparametric equivalents, odds ratios (ORs) with 95% confidence intervals (95% CIs), and receiver operating characteristic (ROC) analysis to assess age-related risk of prolonged symptoms.</p><p><strong>Results: </strong>A total of 570 HZ cases were recorded from 2020 to 2024. Incidence ranged from 1.61 to 2.14 per 1,000 persons and increased with age, reaching 6.57 per 1,000 in individuals aged ≥80 years. Patients aged ≥71 years had higher odds of developing PHN (pain persisting for >90 days) than younger patients (OR = 4.47; 95% CI: 2.30-8.67; p < 0.001). Older adults were also more likely to develop HZO (p = 0.001). Rural incidence was significantly lower during the pandemic than in the post-pandemic period (p = 0.005), with no significant differences in urban or semi-urban areas.</p><p><strong>Conclusions: </strong>The risk of HZ, PHN, and HZO rises with age. During the pandemic (2020-2021), rural incidence was significantly lower than in the post-pandemic period (2022-2024). The study provides updated data on HZ epidemiology in Poland and highlights the impact of the COVID-19 pandemic on healthcare access and HZ reporting in rural areas.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Clinical and Experimental Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.17219/acem/222571","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Herpes zoster (HZ) is caused by reactivation of latent varicella-zoster virus and affects 25-30% of individuals, with the highest incidence in adults aged ≥50 years and a lifetime risk exceeding 50% after the age of 85. Its most common complication is postherpetic neuralgia (PHN), i.e., persistent neuropathic pain. Reports of increased HZ incidence during or after SARS-CoV-2 infection suggest potential epidemiological associations requiring further investigation.

Objectives: Our goals were to evaluate the incidence of HZ and its complications during the pandemic and the post-pandemic period in primary care settings in Poland.

Material and methods: We conducted a retrospective multicenter study in 20 primary care clinics in Poland, covering 43,949-81,091 patients from 2020 to 2024. Incident HZ cases and complications (PHN, herpes zoster ophthalmicus (HZO), HZ oticus, and disseminated HZ) were identified, and demographic data, including place of residence, were collected. Statistical analyses included χ2 or Fisher's exact tests, Student's t-tests or nonparametric equivalents, odds ratios (ORs) with 95% confidence intervals (95% CIs), and receiver operating characteristic (ROC) analysis to assess age-related risk of prolonged symptoms.

Results: A total of 570 HZ cases were recorded from 2020 to 2024. Incidence ranged from 1.61 to 2.14 per 1,000 persons and increased with age, reaching 6.57 per 1,000 in individuals aged ≥80 years. Patients aged ≥71 years had higher odds of developing PHN (pain persisting for >90 days) than younger patients (OR = 4.47; 95% CI: 2.30-8.67; p < 0.001). Older adults were also more likely to develop HZO (p = 0.001). Rural incidence was significantly lower during the pandemic than in the post-pandemic period (p = 0.005), with no significant differences in urban or semi-urban areas.

Conclusions: The risk of HZ, PHN, and HZO rises with age. During the pandemic (2020-2021), rural incidence was significantly lower than in the post-pandemic period (2022-2024). The study provides updated data on HZ epidemiology in Poland and highlights the impact of the COVID-19 pandemic on healthcare access and HZ reporting in rural areas.

2019冠状病毒病大流行期间和之后的带状疱疹流行病学:波兰初级保健的5年回顾性研究
背景:带状疱疹(HZ)是由潜伏的水痘-带状疱疹病毒再激活引起的,影响25-30%的个体,在≥50岁的成年人中发病率最高,85岁以后的终生风险超过50%。最常见的并发症是带状疱疹后神经痛(PHN),即持续性神经性疼痛。在SARS-CoV-2感染期间或之后HZ发病率增加的报告表明,潜在的流行病学关联需要进一步调查。目的:我们的目标是评估波兰初级保健机构在大流行期间和大流行后时期HZ及其并发症的发生率。材料和方法:我们在波兰的20个初级保健诊所进行了一项回顾性多中心研究,涵盖了2020年至2024年的43,949-81,091例患者。确定偶发性HZ病例和并发症(PHN、眼带状疱疹(HZO)、HZ耳部和播散性HZ),并收集包括居住地在内的人口统计数据。统计分析包括χ2或Fisher精确检验、Student's t检验或非参数等效检验、95%置信区间(95% ci)的比值比(ORs)和受试者工作特征(ROC)分析,以评估与年龄相关的症状延长风险。结果:2020 - 2024年共记录570hz病例。发病率从1.61 - 2.14 / 1000人不等,随着年龄的增长而增加,在≥80岁的个体中达到6.57 / 1000人。年龄≥71岁的患者发生PHN(疼痛持续100 ~ 90天)的几率高于年轻患者(OR = 4.47; 95% CI: 2.30 ~ 8.67; p < 0.001)。老年人也更容易患HZO (p = 0.001)。大流行期间农村发病率显著低于大流行后时期(p = 0.005),城市或半城市地区没有显著差异。结论:HZ、PHN、HZO的发病风险随年龄增长而升高。在大流行期间(2020-2021年),农村发病率显著低于大流行后时期(2022-2024年)。该研究提供了波兰赫兹流行病学的最新数据,并强调了COVID-19大流行对农村地区医疗保健可及性和赫兹报告的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Advances in Clinical and Experimental Medicine
Advances in Clinical and Experimental Medicine MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
3.70
自引率
4.80%
发文量
153
审稿时长
6-12 weeks
期刊介绍: Advances in Clinical and Experimental Medicine has been published by the Wroclaw Medical University since 1992. Establishing the medical journal was the idea of Prof. Bogumił Halawa, Chair of the Department of Cardiology, and was fully supported by the Rector of Wroclaw Medical University, Prof. Zbigniew Knapik. Prof. Halawa was also the first editor-in-chief, between 1992-1997. The journal, then entitled "Postępy Medycyny Klinicznej i Doświadczalnej", appeared quarterly. Prof. Leszek Paradowski was editor-in-chief from 1997-1999. In 1998 he initiated alterations in the profile and cover design of the journal which were accepted by the Editorial Board. The title was changed to Advances in Clinical and Experimental Medicine. Articles in English were welcomed. A number of outstanding representatives of medical science from Poland and abroad were invited to participate in the newly established International Editorial Staff. Prof. Antonina Harłozińska-Szmyrka was editor-in-chief in years 2000-2005, in years 2006-2007 once again prof. Leszek Paradowski and prof. Maria Podolak-Dawidziak was editor-in-chief in years 2008-2016. Since 2017 the editor-in chief is prof. Maciej Bagłaj. Since July 2005, original papers have been published only in English. Case reports are no longer accepted. The manuscripts are reviewed by two independent reviewers and a statistical reviewer, and English texts are proofread by a native speaker. The journal has been indexed in several databases: Scopus, Ulrich’sTM International Periodicals Directory, Index Copernicus and since 2007 in Thomson Reuters databases: Science Citation Index Expanded i Journal Citation Reports/Science Edition. In 2010 the journal obtained Impact Factor which is now 1.179 pts. Articles published in the journal are worth 15 points among Polish journals according to the Polish Committee for Scientific Research and 169.43 points according to the Index Copernicus. Since November 7, 2012, Advances in Clinical and Experimental Medicine has been indexed and included in National Library of Medicine’s MEDLINE database. English abstracts printed in the journal are included and searchable using PubMed http://www.ncbi.nlm.nih.gov/pubmed.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书